Literature DB >> 6455927

[On dose-response curves and the receptor interaction of nondepolarizing neuromuscular blocking drugs (author's transl)].

F T Schuh.   

Abstract

1. Dose-response curves of alcuronium, fazadinium, gallamine, metocurine (dimethltubocurarine), pancuronium, and tubocurarine were obtained from 362 surgical patients during general anaesthesia (barbiturate, fentanyl, droperidol, N2O; normoventilation) by means of mechanomyograms of the hand muscles after supramaximal electrical stimulation (100-125 V, 0.2 ms, 0.2 Hz) of the ulnar nerve. - 2. In a conventional semilogarithmic plot of effect E/Emax versus dose D the sigmoid-shaped curves exhibit a parallel shift with almost the same slopes. - 3. A linear plot of E/Emax against D yields curves intersecting by extrapolation with the ordinate at a point s below zero which indicates a threshold phenomenon in the dose-response relation and gives the value for this threshold (s=60-80). - 4. A double-reciprocal plot of 1/(E/Emax) versus 1/D does not result in straight lines, indicating a lack of linear proportionality between receptor occupancy and effect. The curves are straightened plotting 1/[(E+S)/(Emax+S)] versus 1/D. - 5. From our results which are supported by the "margin of safety" concept of neuromuscular transmission, it is supposed that the relation between neuromuscular blocking drugs and nicotinic receptors does not follow the classical occupation theory based on the law of mass action.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6455927

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  1 in total

1.  Effects of presynaptic muscarinic cholinoreceptor blockade on neuromuscular transmission as assessed by the train-of-four and the tetanic fade response to rocuronium.

Authors:  Yong Beom Kim; Sangseok Lee; Kyeong Chun Lee; Ha Jung Kim; Young Jin Ro; Hong-Seuk Yang
Journal:  Clin Exp Pharmacol Physiol       Date:  2017-07       Impact factor: 2.557

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.